Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

LLY Relative to the S&P 500

LLY Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Eli Lilly & Co. (NYSE:LLY) seasonal charts above shows that a Buy Date of October 25 and a Sell Date of January 21 has resulted in a geometric average return of 5.51% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 15 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 3.08% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly’s key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

To download LLY seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: LLY